Shopping Cart
×

Bay City Capital

Bay City Capital

  • San Francisco, California, United States

  • San Francisco, California

Stage

  • Debt, Early Stage, Late Stage, Private Equity

Type

  • Venture Capital

Description

Established in 1997, Bay City Capital LLC manages investment funds in the life sciences industry. With six venture funds totaling $1.5 billion, they have invested in over 70 companies, spanning general life sciences and the nutrition and agribusiness sectors.

Mission

A global diversified strategy ranging from seed stage to public companies, and including innovation, restructuring opportunities, and growth investing.

Beauty Investments #

  • 1

Primary Sector

  • Biotechnology,Health Care, Medical

Beauty Exits #

  • 0

Last Beauty Invest

  • Jul, 2013-Tria Beauty

BEAUTY PORTFOLIO

How to Apply?

stacey@baycitycapital.com

Criteria

CONSISTENT INVESTMENT APPROACH
Bay City Capital seeks to invest its capital in life sciences companies where our operational, financial, and scientific expertise can assist management in building companies. This investment approach has remained largely consistent since 1997.

90% Board Representation 86% lead or co-lead Investor
Partnering with Effective Management
Effective management is critical to the success of our portfolio companies. We assist our portfolio companies in recruiting and retaining key management and advisors, identifying product opportunities, establishing and negotiating strategic partnerships, and providing assistance with product development and execution. We develop close working relationships with our management teams to establish ourselves as true partners in business building. We strongly prefer board representation, and have received a board seat with 90% of our portfolio companies (based on invested capital). We believe this commitment of intellectual capital increases the likelihood of positive outcomes for our investments, and has established us as a preferred partner in the industry.

270 Co-Investors $3.60 Syndication Multiplier
Lead Investor and Syndication
We are typically a lead or co-lead investor in our investments, and have done so 86% of the time (based on invested capital). 270 investor groups have co-invested in Bay City Capital portfolio companies, providing these companies with significant capital beyond our investment. More specifically, for $1.00 invested by Bay City Capital, an additional $3.60 was invested by co-investors.

Liquidity Events
Achieving liquidity for our portfolio companies is an essential component of our investment performance. Not surprisingly, mergers and acquisitions represent our primary exit path, one that is not dependent upon the public market perception of life sciences companies at the time of exit. To help facilitate the acquisition of our portfolio companies, we have developed an extensive network throughout the life sciences industry. We have also encouraged potential acquirers to make co-investments in our portfolio companies early in the development stage. We believe such early and continued involvement from strategic investors increases the likelihood of a successful outcome.

Resources Breakdown Funding Terms
  • $800K To $6.8M

  • N/A

Education
  • No
Accelerator
  • Type-No
  • Duration-No
Network
  • 131
1:1
  • Yes

IMPERATIVE: CULTURE & VALUES

TBD

TBD

TBD

TBD

TBD

TBD

BEAUTY FUNDER FIT SCORE

Resources

Education

Accelerator

Network

1:1

1.65/10

*This score calculates the likelihood of any beauty brand getting funded by the investor. The score gives weights to number of beauty investments, recency of beauty investment, number of beauty exits, inclusivity inclination, resources offered, etc.

Inclusivity Investments %
  • 10.69%
Beauty Investments #
  • 1

Beauty Exits #
  • 0
Last Beauty Invest
  • Jul, 2013-Tria Beauty

LEAD DETAILS

Lead Contact

Matt Kronmiller

Title

Vice President

LinkedIn

Twitter Handle

Bay City Capital

Contact

matt@baycitycapital.com

1(415)676-3830

JUMP CONCLUSION

Bay City Capital targets early to mid-stage life sciences companies globally, with a focus on biotechnology and pharmaceuticals. Based in San Francisco, they emphasize collaborations in investment rather than leading roles, showcasing interest in innovative sectors like biopharma, therapeutics, and health diagnostics.

Layer 1